Boston researchers have shown how cancer genome evolution alters clinical outcomes in chronic lymphocytic leukemia, and a Michigan team has identified a new transcriptional fusion that could contribute to CLL. Both studies could guide the development of new diagnostics and therapeutics for the blood cancer.